Glyset
Glyset

2.17
Intended to relieve postprandial blood sugar spikes to support long-term diabetes management and target carbohydrate absorption.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Miglitol
Reference Brand
Miglitol
Product Origin
Generic Alternative
Reference Manufacturer
Pharmacia & Upjohn
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Antidiabetics
Product Category
Alpha-Glucosidase Inhibitor
Pharmacological Class
Antidiabetic
Clinical Indications
Manufacturer Description
Intended to relieve postprandial blood sugar spikes to support long-term diabetes management and target carbohydrate absorption.
Mechanism of Action
Reversibly inhibits membrane-bound intestinal alpha-glucoside hydrolase enzymes, delaying the absorption of complex carbohydrates.
Route of Administration
Oral
Onset Time
30 minutes
Duration
4–6 hours
Contraindications
Inflammatory bowel disease, Colonic ulceration, Partial intestinal obstruction
Severe Adverse Events
Severe intestinal obstruction — requires immediate medical attention
Common Side Effects
Flatulence, Diarrhea, Abdominal pain
Uncommon Side Effects
Abdominal distension, Mild skin rash, Iron deficiency
Drug Interactions
Digoxin, Ranitidine, Digestive Enzymes
Pregnancy Safety Warnings
TGA Category B: Safety demonstrated in animal studies. Breastfeeding: Expelled in low quantities.
Age Restrictions
Approved for adults.
Storage Guidelines
Store below 25°C.
Related Products
Information related to Glyset is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
how to purchase Cancer Support Medication - Buy Capecitabine AU